Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

Medicine, Oncology, Pharmacology +16

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 433 citations · Full text

Medicine, Oncology, Pharmacology +16

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Mariangela Russo, Sandra Misale, Wei Ge et al. · Cancer Discovery · 2015 · 304 citations · Full text

Medicine, Molecular Biology, Oncology +17

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Anna F. Farago, Long P. Le, Zongli Zheng et al. · Journal of Thoracic Oncology · 2015 · 226 citations · Full text

Medicine, Oncology, Pharmacology +10